Matching articles for "Gemtesa"
Issue 1672 · March 20, 2023
Drugs for Overactive Bladder

In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age.…

Med Lett Drugs Ther. 2023 Mar 20; 65(1672):41-5 doi:10.58347/tml.2023.1672a
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Issue 1649 · May 2, 2022
Drugs for Benign Prostatic Hyperplasia

About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent…

Med Lett Drugs Ther. 2022 May 2; 64(1649):65-9
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Issue 1623 · May 3, 2021 Free
Vibegron (Gemtesa) for Overactive Bladder

The FDA has approved the selective beta-3 adrenergic agonist vibegron ( Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and…

Med Lett Drugs Ther. 2021 May 3; 63(1623):67-9
The FDA has approved the selective beta-3 adrenergic agonist vibegron ( Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is the second beta-3 agonist to be approved in the US; mirabegron (Myrbetriq) was the first.